PHSE Group, a leading global provider of temperature-controlled and time-critical pharmaceutical logistics, announces the acquisition of an 80% stake in Optimize Courier Sweden AB and its subsidiary Optimize Courier Denmark ApS, a specialized Nordic operator with strong expertise in the transportation of temperature-sensitive healthcare products, particularly in international import and export operations.
Through this strategic acquisition, PHSE Group establishes a solid presence in two new key markets, Sweden and Denmark, while significantly strengthening its Global Forwarding segment. This expansion further reinforces the Group’s capability to deliver urgent shipments of pharmaceuticals, biological samples, clinical trials, and dangerous goods across international markets.
Founded approximately 20 years ago by Jan Karlsson, Optimize Courier has built a strong reputation as a Nordic market leader with operational hubs in Stockholm and Copenhagen. Over two decades, the company has developed proven expertise in handling temperature-sensitive healthcare products, serving pharmaceutical companies, research centers, and hospitals across multiple countries. With approximately 60% of its business focused on exports, 70% to European destinations and 30% to the United States, Optimize Courier brings a robust international footprint that complements PHSE Group’s global network.
Both facilities hold IATA accreditation and are strategically located near major airports, providing optimal connectivity for critical time-sensitive international shipments across Northern Europe.
“Expanding our territorial coverage across Northern European markets represents a strategic priority for PHSE,” said Fabio Mioli, CEO of PHSE International. . “This integration brings specialized expertise and infrastructure that align precisely with our long-term expansion strategy. We plan to enhance their service portfolio, particularly in the radiopharmaceutical segment, leveraging our extensive know-how and established commercial relationships.”
Jan Karlsson, alongside his sons Marcus and Adam, will continue their involvement in the business, bringing invaluable local market knowledge and entrepreneurial expertise to the enlarged operation.
“I am very pleased to join the wider PHSE Group with all the knowledge and expertise it has to offer,” commented Jan Karlsson.. “This partnership will enable us to leverage our combined capabilities to better serve our pharmaceutical and logistics partners across the Nordic region and beyond.”
With this transaction, PHSE Group reinforces its position as a leading specialist in its sector, where highly sensitive biological materials and urgent deliveries demand absolute precision and uncompromised speed.
Supported by a global network of validated partners, PHSE Group today operates 41 facilities worldwide, employing more than 780 people and running a fleet of approximately 630 specialist vehicles. In 2025, the Group recorded pro-forma revenues of 120 million euros.
PHSE Group
With proven expertise in the sector, PHSE manages the transportation and shipment of high-value pharmaceutical products, biotech, clinical trials, biological samples, radiopharmaceuticals, cell & gene therapies. The company serves vital delivery channels including hospitals, home care services, clinical laboratories, and nuclear medicine departments worldwide. Our extensive presence spans direct branches across North America, South America, Europe, United Kingdom, Asia, and a qualified network of certified agents for seamless worldwide coverage. We operate on a multimodal scale by land, air, and sea, ensuring flexible and reliable temperature-controlled logistics solutions for every critical transportation need.
